Лучшие больницы для «Breast Biopsy» в Хайдарабад, Индия

In India, a breast biopsy at a JCI- or NABH-accredited hospital costs approximately USD 300–1,200 depending on the technique used. Ultrasound-guided core needle biopsy (CNB) at the lower end of this range typically costs USD 300–600, while MRI-guided vacuum-assisted biopsy or open surgical excisional biopsy with full IHC pathology panels falls in the USD 800–1,200 range. In the UAE (Dubai or Abu Dhabi), the same procedures at JCI- and DHA-licensed centres typically cost USD 800–2,800, with the higher figure applying to MRI-guided biopsy with advanced genomic profiling. India is therefore approximately 50–65% less expensive than the UAE for equivalent diagnostic quality. Both destinations offer inclusive packages covering consultation, imaging guidance, the biopsy procedure itself, standard histopathology (H&E), immunohistochemistry (ER, PR, HER2, Ki-67), and one post-procedure review. Additional costs such as FISH testing for HER2 amplification, Oncotype DX genomic profiling, or repeat biopsy are quoted separately. GAF Healthcare provides transparent, fixed-price packages for both destinations with no hidden facility fees.

The required in-country stay depends on the biopsy technique performed. For the most common procedure — ultrasound-guided core needle biopsy or stereotactic vacuum-assisted biopsy (VAB) — patients are typically fit to fly within 3–7 days. This window allows time for the wound to heal, a post-procedure review ultrasound to exclude haematoma, and crucially, receipt of standard histopathology results (3–5 working days) and IHC results (5–7 working days) before departure, so that the patient leaves with a confirmed diagnosis rather than awaiting results at home. For open surgical (excisional) biopsy performed under general anaesthesia, the recommended in-country stay is 14–21 days to allow wound healing, suture removal (Day 10–14), and surgeon clearance. Long-haul flights (>6 hours) are generally safe after percutaneous biopsy with no increased thromboembolic risk specific to the procedure itself, though patients should follow standard deep vein thrombosis prevention measures (hydration, compression stockings, periodic ambulation). GAF Healthcare's case manager confirms the fit-to-fly date with the treating surgeon and provides a formal medical clearance letter for airline and travel insurance purposes.

Breast biopsy is not a therapeutic procedure — its 'success' is measured by diagnostic accuracy rather than a curative outcome. Image-guided core needle biopsy (CNB) and vacuum-assisted biopsy (VAB) achieve diagnostic accuracy rates of 97–99% for characterising breast lesions when performed by experienced interventional radiologists or breast surgeons under real-time imaging guidance. Sensitivity for malignancy detection exceeds 95%, and specificity exceeds 96% in high-volume centres. The false-negative rate — the risk of a cancerous lesion being misclassified as benign — is approximately 1–5% for CNB and less than 1% for VAB, provided that radiological-pathological concordance review is performed after every biopsy (a mandatory quality standard at all GAF Healthcare partner hospitals). False negatives are most often due to sampling error rather than pathological misinterpretation and are managed by radiological-pathological discordance protocol: any result that does not explain the imaging findings is escalated for repeat biopsy or surgical excision. MRI-guided biopsy carries a technical failure rate of approximately 3–5% due to lesion enhancement variability between the diagnostic MRI and the biopsy session, which is mitigated by same-day contrast MRI localisation before needle insertion. When pathology confirms malignancy, subsequent treatment decisions — including surgery, HER2-targeted therapy (trastuzumab, pertuzumab), CDK4/6 inhibitors for hormone receptor-positive disease, or PARP inhibitors for BRCA-mutated cancers — are based on the biopsy's receptor profile and genomic data, making the accuracy of the biopsy report foundational to the entire treatment pathway.